CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

1. CNS Specific Antisense Oligonucleotide Market - CNS Specific Antisense Oligonucleotide Market - Size, Share, Growth, Outlook, and Opportunity Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Analysis, 2018-2026 Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modifcation of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development. Market Dynamics Increasing prevalence of neurodegenerative disease is a major factor driving CNS specifc antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2477 Increasing prevalence of cancer is expected to propel growth of the CNS specifc antisense oligonucleotide market CNS specifc antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases. According to February 2017, report of National Center for Biotechnology Information (NCBI), an estimated the prevalence of Cerebral palsy ranges from 1.5 to more than 4 per 1,000 of children from age 10 to 14 years. The birth prevalence of Cerebral palsy is around 2 per 1,000 live births globally. Furthermore, launch of new products for rare disease associated with CNS disorders is propelling growth of the CNS specifc antisense oligonucleotide market over the forecast period. For

2. instance, in October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its novel drug TEGSEDITM (inotersen) indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In the same year, company received approval from Canadian Health authority for the novel drug TEGSEDITM (inotersen). However, high cost of treatment and risk of toxicity is expected to hinder the market growth. According to the Journal Molecular Therapy, in May 2017, Biogen priced Spinraza (nusinersen injection) at US$ 750,000 for the frst year’s treatment (US$125,000 per injection) and US$350,000 per year. Report includes chapters which deeply display the following deliverable about industry : • CNS Specific Antisense Oligonucleotide Market Research Objective and Assumption • CNS Specific Antisense Oligonucleotide Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • CNS Specific Antisense Oligonucleotide Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global CNS Specific Antisense Oligonucleotide Market, By Regions • CNS Specific Antisense Oligonucleotide Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • CNS Specific Antisense Oligonucleotide Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • CNS Specific Antisense Oligonucleotide Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • CNS Specific Antisense Oligonucleotide Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and Q-STATE BIOSCIENCES, INC. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2477

3. Detailed Segmentation: Global CNS Specifc Antisense Oligonucleotide Market, By Drug: • Approved • Patisiran • Nusinersen • Inotersen • Pipeline • IONIS-HTT Rx (RG6042) Global CNS Specifc Antisense Oligonucleotide Market, By Indication: • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy • Spinal Muscular Atrophy • Huntington’s Disease Global CNS Specifc Antisense Oligonucleotide Market, By Distribution Channel: • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy Global CNS Specifc Antisense Oligonucleotide Market, By Geography: • North America • • • • Europe • Asia Pacifc • Latin America • Middle East • Africa • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200

4. Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com